Phase IIa

MELBOURNE, Australia — September 15, 2026 ENA Respiratory announced that the first participants have been dosed in Part B...

BARCELONA, Spain — September 10, 2026 CONNECTA Therapeutics announced the closing of a €3.1 million financing led by new...

ALDERLEY PARK, Cheshire, U.K. — September 8, 2026 Infex Therapeutics presented new data from its Phase IIa study of...

Vancouver, Canada — September 1, 2026 Clearmind Medicine Inc. announced the initiation of Phase IIa development for CMND-100, its...

Alderley Park, Cheshire, U.K., August 19, 2026 Infex Therapeutics will present new Phase IIa data for RESP-X (INFEX702) in...

Find Jobs Across Pharma, Biotech & Life Sciences

Discover verified job opportunities from top companies worldwide. Apply easily and grow your career in the life sciences industry.

Alderley Park, Cheshire, U.K., May 21, 2026 Infex Therapeutics announced positive Phase IIa clinical trial results for RESP-X (INFEX702)...

Nes-Ziona, Israel — Nov. 24, 2025 — Enlivex Therapeutics Ltd. announced positive six-month topline results from the Phase IIa...